ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
78
HLB Life Science Enters Licensing Agreement with Jiangsu Hengrui Medicine for Targeted Anti-Cancer Therapy Pyrotinib
admin
2020.09.29
77
HLB receives IND approval from MFDS for global clinical trial for colon cancer treatment
admin
2020.09.24
76
HLB confirms Superior mPFS of Phase III Results of Rivoceranib on NSCLC
admin
2020.09.21
75
HLB opens the result of Phase III Results of Rivoceranib on Thyroid Cancer at ESMO
admin
2020.09.18
74
HLB draws a ‘Meaningful Result’ from Rivoceranib on Esophageal Cancer
admin
2020.09.17
73
HLB announces Rivoceranib Combo Phase II Results on Liver Cancer
admin
2020.09.15
72
ITI to Participate at World Vaccine Congress Washington 2020
admin
2020.09.15
71
HLB secures Global Rights of Rivoceranib and becomes a Royalty-receiving Company
admin
2020.09.07
70
Immunomic Therapeutics selected as a key player of COVID-19 vaccine development
admin
2020.08.18
69
HLB receives IND Approval for the Global Phase III of Primary Liver Cancer Treatment from KFDA
admin
2020.08.13
1
2
3
4
5
6
7
8
9
10
>
>>